Infliximab infusion time in patients with inflammatory bowel diseases: Is longer really safer? - 16/04/13
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/204e.gif)
pages | 4 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Summary |
Background and objective |
Infliximab, a monoclonal antibody directed against tumor necrosis factor ⍺ (TNF⍺), is commonly used during flares and on a regular basis to maintain the remission of inflammatory bowel diseases (IBD). It is usually administered in 2-hours infusion and 2hours of monitoring after as recommended. However, recent reports suggest that infliximab infusions over a shorter period (30minutes to 1hour) are well tolerated. We aimed to compare the tolerability of 1-hour and 2-hours infliximab infusions in patients with IBD in our institution.
Methods |
We analyzed data from all patients treated with infliximab between 1999 and September 2010. Infliximab was administered in 1-hour infusion and 1 hour monitoring since 2009. Only the early adverse events were analyzed.
Results |
Adverse events during infusion were compared between one group of patients who had 1-hour infusion (989 infusions) and the other who had 2-hours infusion (2102 infusions). The incidence of adverse events was 10.6% in the 2-hours infusion group versus 6.3% in the 1-hour infusion group (P=0.36).
Conclusions |
These results suggest that the occurrence of infliximab infusion-related adverse events is similar across the two groups, regardless of the infusion cycle. One-hour infusion could then be proposed safely for all patients.
Le texte complet de cet article est disponible en PDF.Plan
Vol 37 - N° 2
P. 189-192 - avril 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?